Nanomerics is a speciality pharmaceutical company which was spun out from University College London. Nanomerics creates differentiated medicines based on its patented Molecular Envelope Technology (MET).
Prof Ijeoma UchegbuChief Scientific Officer
Nascient Ltd is a funded, privately-held biotech company developing novel therapies for the treatment of inflammatory diseases.
Based in the United Kingdom, Nascient is developing Matriximab, a fully human mAb targeting the Fibrinogen Globe (FBG) of Tenascin C. FBG is a novel therapeutic target involved in the initiation of acute inflammation and the onset of chronic disease.
Nascient is funded by Imperial Innovations.